A bipartisan group of lawmakers wants a bipartisan bill to lower insulin prices to also outlaw drug rebates for the key diabetes treatment.
The collection of bipartisan House and Senate lawmakers released a list of top policy priorities for limiting insulin costs, a major policy priority for Congress.
“Our proposal holds all parties accountable by encouraging them to reduce list prices, and critically, it limits out-of-pocket costs for patients with diabetes,” said Sens. Jeanne Shaheen, D-New Hampshire, and Susan Collins, R-Maine, in a joint statement. Reps. Diana Degette, D-Colorado and Tom Reed, R-New York, also joined the announcement.
